Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report
Jazyk angličtina Země Česko Médium print-electronic
Typ dokumentu kazuistiky, časopisecké články
PubMed
26725706
DOI
10.5507/bp.2015.061
Knihovny.cz E-zdroje
- Klíčová slova
- esophageal melanoma, masitinib, targeted therapy,
- MeSH
- benzamidy MeSH
- exony MeSH
- fatální výsledek MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- melanom farmakoterapie sekundární MeSH
- mutace genetika MeSH
- nádory jícnu farmakoterapie MeSH
- nádory mozku farmakoterapie sekundární MeSH
- piperidiny MeSH
- protoonkogenní proteiny c-kit genetika MeSH
- pyridiny MeSH
- thiazoly terapeutické užití MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- Názvy látek
- benzamidy MeSH
- inhibitory proteinkinas MeSH
- masitinib MeSH Prohlížeč
- piperidiny MeSH
- protoonkogenní proteiny c-kit MeSH
- pyridiny MeSH
- thiazoly MeSH
BACKGROUND: Malignant melanoma in the gastrointestinal tract may be primary or metastatic. Mucosal melanoma is a quite rare and aggressive disease, growing hidden and diagnosed with a certain delay which makes treatment difficult. CASE REPORT: The authors present the first patient with c-kit exon 11 mutated primary esophageal melanoma treated with oral tyrosine kinase inhibitor masitinib. A 55-year-old-man presented with esophageal melanoma metastising into visceral organs and to the brain. The patient showed objective and clinical significant therapeutic response to masitinib. After initiation of masitinib, dysphagia and odynophagia disappeared within 1 week. Following 1 month of treatment, computed tomography showed a regression in the number and size of brain metastatic lesions and regression in visceral lesions. This therapeutic response, despite the aggressive disease on treatment initiation, effectively enabled the patient to have 6 months of quality life. CONCLUSION: This report corroborates the plausibility of treating advanced melanoma carrying a mutation of KIT with masitinib. It also raises the question of masitinib treatment beyond progression. Additionally, the observed masitinib treatment effect on the brain suggests accumulation of therapeutically relevant concentration of masitinib in the central nervous system. This observation has possible ramifications for treatment of intracranial neoplasms.
Department of Clinical Oncology and Radiotherapy University Hospital in Hradec Kralove
Department of Clinical Oncology County Hospital Nachod Czech Republic
Department of Histopathology County Hospital Nachod
Citace poskytuje Crossref.org
